Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite

Ivo Mueller, Mary R. Galinski, J. Kevin Baird, Jane M. Carlton, Dhanpat K. Kochar, Pedro L. Alonso, Hernando A. del Portillo

Research output: Contribution to journalArticle

Abstract

Plasmodium vivax is geographically the most widely distributed cause of malaria in people, with up to 2·5 billion people at risk and an estimated 80 million to 300 million clinical cases every year-including severe disease and death. Despite this large burden of disease, P vivax is overlooked and left in the shadow of the enormous problem caused by Plasmodium falciparum in sub-Saharan Africa. The technological advances enabling the sequencing of the P vivax genome and a recent call for worldwide malaria eradication have together placed new emphasis on the importance of addressing P vivax as a major public health problem. However, because of this parasite's biology, it is especially difficult to interrupt the transmission of P vivax, and experts agree that the available methods for preventing and treating infections with P vivax are inadequate. It is thus imperative that the development of new methods and strategies become a priority. Advancing the development of such methods needs renewed emphasis on understanding the biology, pathogenesis, and epidemiology of P vivax. This Review critically examines what is known about P vivax, focusing on identifying the crucial gaps that create obstacles to the elimination of this parasite in human populations.

Original languageEnglish (US)
Pages (from-to)555-566
Number of pages12
JournalThe Lancet Infectious Diseases
Volume9
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Plasmodium vivax
Malaria
Parasites
Africa South of the Sahara
Plasmodium falciparum
Epidemiology
Public Health
Genome
Infection
Population

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Mueller, I., Galinski, M. R., Baird, J. K., Carlton, J. M., Kochar, D. K., Alonso, P. L., & del Portillo, H. A. (2009). Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. The Lancet Infectious Diseases, 9(9), 555-566. https://doi.org/10.1016/S1473-3099(09)70177-X

Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. / Mueller, Ivo; Galinski, Mary R.; Baird, J. Kevin; Carlton, Jane M.; Kochar, Dhanpat K.; Alonso, Pedro L.; del Portillo, Hernando A.

In: The Lancet Infectious Diseases, Vol. 9, No. 9, 09.2009, p. 555-566.

Research output: Contribution to journalArticle

Mueller, I, Galinski, MR, Baird, JK, Carlton, JM, Kochar, DK, Alonso, PL & del Portillo, HA 2009, 'Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite', The Lancet Infectious Diseases, vol. 9, no. 9, pp. 555-566. https://doi.org/10.1016/S1473-3099(09)70177-X
Mueller, Ivo ; Galinski, Mary R. ; Baird, J. Kevin ; Carlton, Jane M. ; Kochar, Dhanpat K. ; Alonso, Pedro L. ; del Portillo, Hernando A. / Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. In: The Lancet Infectious Diseases. 2009 ; Vol. 9, No. 9. pp. 555-566.
@article{58875c4037bb416d8a5b1223cc2fd666,
title = "Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite",
abstract = "Plasmodium vivax is geographically the most widely distributed cause of malaria in people, with up to 2·5 billion people at risk and an estimated 80 million to 300 million clinical cases every year-including severe disease and death. Despite this large burden of disease, P vivax is overlooked and left in the shadow of the enormous problem caused by Plasmodium falciparum in sub-Saharan Africa. The technological advances enabling the sequencing of the P vivax genome and a recent call for worldwide malaria eradication have together placed new emphasis on the importance of addressing P vivax as a major public health problem. However, because of this parasite's biology, it is especially difficult to interrupt the transmission of P vivax, and experts agree that the available methods for preventing and treating infections with P vivax are inadequate. It is thus imperative that the development of new methods and strategies become a priority. Advancing the development of such methods needs renewed emphasis on understanding the biology, pathogenesis, and epidemiology of P vivax. This Review critically examines what is known about P vivax, focusing on identifying the crucial gaps that create obstacles to the elimination of this parasite in human populations.",
author = "Ivo Mueller and Galinski, {Mary R.} and Baird, {J. Kevin} and Carlton, {Jane M.} and Kochar, {Dhanpat K.} and Alonso, {Pedro L.} and {del Portillo}, {Hernando A.}",
year = "2009",
month = "9",
doi = "10.1016/S1473-3099(09)70177-X",
language = "English (US)",
volume = "9",
pages = "555--566",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite

AU - Mueller, Ivo

AU - Galinski, Mary R.

AU - Baird, J. Kevin

AU - Carlton, Jane M.

AU - Kochar, Dhanpat K.

AU - Alonso, Pedro L.

AU - del Portillo, Hernando A.

PY - 2009/9

Y1 - 2009/9

N2 - Plasmodium vivax is geographically the most widely distributed cause of malaria in people, with up to 2·5 billion people at risk and an estimated 80 million to 300 million clinical cases every year-including severe disease and death. Despite this large burden of disease, P vivax is overlooked and left in the shadow of the enormous problem caused by Plasmodium falciparum in sub-Saharan Africa. The technological advances enabling the sequencing of the P vivax genome and a recent call for worldwide malaria eradication have together placed new emphasis on the importance of addressing P vivax as a major public health problem. However, because of this parasite's biology, it is especially difficult to interrupt the transmission of P vivax, and experts agree that the available methods for preventing and treating infections with P vivax are inadequate. It is thus imperative that the development of new methods and strategies become a priority. Advancing the development of such methods needs renewed emphasis on understanding the biology, pathogenesis, and epidemiology of P vivax. This Review critically examines what is known about P vivax, focusing on identifying the crucial gaps that create obstacles to the elimination of this parasite in human populations.

AB - Plasmodium vivax is geographically the most widely distributed cause of malaria in people, with up to 2·5 billion people at risk and an estimated 80 million to 300 million clinical cases every year-including severe disease and death. Despite this large burden of disease, P vivax is overlooked and left in the shadow of the enormous problem caused by Plasmodium falciparum in sub-Saharan Africa. The technological advances enabling the sequencing of the P vivax genome and a recent call for worldwide malaria eradication have together placed new emphasis on the importance of addressing P vivax as a major public health problem. However, because of this parasite's biology, it is especially difficult to interrupt the transmission of P vivax, and experts agree that the available methods for preventing and treating infections with P vivax are inadequate. It is thus imperative that the development of new methods and strategies become a priority. Advancing the development of such methods needs renewed emphasis on understanding the biology, pathogenesis, and epidemiology of P vivax. This Review critically examines what is known about P vivax, focusing on identifying the crucial gaps that create obstacles to the elimination of this parasite in human populations.

UR - http://www.scopus.com/inward/record.url?scp=68949106269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949106269&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(09)70177-X

DO - 10.1016/S1473-3099(09)70177-X

M3 - Article

C2 - 19695492

AN - SCOPUS:68949106269

VL - 9

SP - 555

EP - 566

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 9

ER -